Everolimus and sunitinib: From mouse models to treatment of pancreatic neuroendocrine tumors

Future Oncology

Volumn 7, Issue 9, 2011, Pages 1025-1029

  Liakakos, Theodore ^a   Roukos, Dimitrios H ^b,c  

^a UNIVERSITY OF ATHENS   (Greece)

^b UNIVERSITY OF IOANNINA   (Greece)

^c UNIVERSITY OF IOANNINA   (Greece)

Author keywords

advanced pancreatic cancer; everolimus; neuroendocrine tumor; sunitinib; survival; systemic treatment; translational medicine

Indexed keywords

BEVACIZUMAB; CHROMOGRANIN A; DOXORUBICIN; ERLOTINIB; EVEROLIMUS; PLACEBO; PLATELET DERIVED GROWTH FACTOR RECEPTOR; SOMATOSTATIN DERIVATIVE; STREPTOZOCIN; SUNITINIB; VASCULOTROPIN RECEPTOR;

ANGIOGENESIS; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; CANCER CELL; CANCER COMBINATION CHEMOTHERAPY; CANCER INVASION; CANCER STAGING; CANCER SURGERY; CANCER SURVIVAL; CELL DEATH; CELL GROWTH; CELL PROLIFERATION; COMPUTER ASSISTED TOMOGRAPHY; DISEASE COURSE; DRUG EFFICACY; DRUG SAFETY; ENDOSCOPIC ECHOGRAPHY; ENDOSCOPY; METASTASIS; NEUROENDOCRINE TUMOR; NONHUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; ONCOGENE; OVERALL SURVIVAL; PANCREAS ISLET CELL TUMOR; PANCREATIC NEUROENDOCRINE TUMOR; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; REVIEW; TUMOR DIAGNOSIS; TUMOR VOLUME;

ANGIOGENESIS INHIBITORS; ANIMALS; ANTINEOPLASTIC AGENTS; CARCINOMA, NEUROENDOCRINE; DISEASE MODELS, ANIMAL; HUMANS; INDOLES; MICE; PANCREATIC NEOPLASMS; PYRROLES; SIROLIMUS; TOR SERINE-THREONINE KINASES;

EID: 80053029659     PISSN: 14796694     EISSN: 17448301     Source Type: Journal    
DOI: 10.2217/fon.11.88     Document Type: Review

References (29)

1. Yao JC, Lombard-Bohas C, Baudin E et al. Daily oral everolimus activity in patients with metastatic pancreatic neuroendocrine tumors after failure of cytotoxic chemotherapy: a Phase II trial. J. Clin. Oncol. 28, 69-76 (2010).
2. O'Donnell A, Faivre S, Burris HA III et al. Phase I pharmacokinetic and pharmacodynamic study of the oral mammalian target of rapamycin inhibitor everolimus in patients with advanced solid tumors. J. Clin. Oncol. 26, 1588-1595 (2008).
3. Faivre S, Demetri G, Sargent W, Raymond E. Molecular basis for sunitinib efficacy and future clinical development. Nat. Rev. Drug Discov. 6, 734-745 (2007). (Pubitemid 47338181)
4. Yao JC, Shah MH, Ito T et al. Everolimus for advanced pancreatic neuroendocrine tumors. N. Engl. J. Med. 364, 514-523 (2011).
5. Raymond E, Dahan L, Raoul J-L et al. Sunitinib malate for the treatment of pancreatic neuroendocrine tumors. N. Engl. J. Med. 364, 501-513 (2011).
6. Metz DC, Jensen RT. Gastrointestinal neuroendocrine tumors: pancreatic endocrin tumors. Gastroenterology 135, 1469-1492 (2008).
7. Panzuto F, Nasoni S, Falconi M et al. Prognostic factors and survival in endocrine tumor patients: comparison between gastrointestinal and pancreatic localization. Endocr. Relat. Cancer 12, 1083-1092 (2005). (Pubitemid 41815799)
8. Yao JC, Hassan M, Phan A et al. One hundred years after 'carcinoid': epidemiology of and prognostic factors for neuroendocrine tumors in 35, 825 cases in the United States. J. Clin. Oncol. 26, 3063-3072 (2008).
9. Fischer L, Kleeff J, Esposito I et al. Clinical outcome and long-term survival in 118 consecut ive patients with neuroendocrine tumours of the pancreas. Br. J. Surg. 95, 627-635 (2008). e
10. Fischer L, Mehrabi A, Büchler M W. Neuroendocrine tumors of the duodenum and pancreas: surgical strategy. Chirurg 82(7), 583-590 (2011).
11. Kloppel G, Rindi G, Perren A et al. The ENETS and UICC TNM classification of neuroendocrine tu mors of the gastrointestinal tract and the pancre as: comment. Pathologe 31, 353-354 (2010).
12. Hauso O, Gustafsson BI, Kidd M et al. Neuroendocrine tumor epidemiology: contrasting Norway and North America. Cancer 113, 2655-2664 (2008).
13. Cheng PNM, Saltz LB. Failure to confirm major objective antitumor activity for streptozocin and doxorubicin in the treatment of patients with advanced islet cell carcinoma. Cancer 86, 944-948 (1999). (Pubitemid 29439847)
14. Bajetta E, Procopio G, Ferrari L et al. Update on the treatment of neuroendocrine tumors. Expert Rev. Anticancer Ther. 3, 631-642 (2003). (Pubitemid 37337104)
15. Kouvaraki MA, Ajani JA, Hoff P et al. Fluorouracil, doxorubicin, and streptozocin in the treatment of patients with locally advanced and metastatic pancreatic endocrine carcinomas. J. Clin. Oncol. 22, 4762-4771 (2004).
16. McCollum AD, Kulke MH, Ryan DP et al. Lack of efficacy of streptozocin and doxorubicin in patients with advanced pancreatic endocrine tumors. Am. J. Clin. Oncol. 27, 485-488 (2004). (Pubitemid 39371944)
17. Rinke A, Móller HH, Schade-Brittinger C et al. Placebo-controlled, double-blind, prospective, randomized study on the effect of octreotide LAR in the control of tumor growth in patients with metastatic neuroendocrine midgut tumors: a report from the PROMID Study Group. J. Clin. Oncol. 27, 4656-4663 (2009).
18. Hanahan D, Weinberg RA. Hallmarks of cancer: the next generation. Cell 144(5), 646-674 (2011).
19. Chaffer CL, Weinberg RA. A perspective on cancer cell metastasis. Science 2331(6024), 1559-1564 (2011).
20. Frese KK, Tuveson DA. Maximizing mouse cancer models. Nat. Rev. Cancer 7, 645-658 (2007). (Pubitemid 47327410)
21. Tuveson D, Hanahan D. Translational medicine: cancer lessons from mice to humans. Nature 471(7338), 316-317 (2011).
22. Hanahan D. Heritable formation of pancreatic β-cell tumours in transgenic mice expressing recombinant insulin/simian virus 40 oncogenes. Nature 315, 115-122 (1985). (Pubitemid 15064530)
23. Missiaglia E, Dalai I, Barbi S et al. Pancreatic endocrine tumors: expression profiling evidences a role for AKT-mTOR pathway. J. Clin. Oncol. 28, 245-255 (2010).
24. Inoue M, Hager JH, Ferrara N, Gerber HP, Hanahan D. VEGF-A has a critical, nonredundant role in angiogenic switching and pancreatic β cell carcinogenesis. Cancer Cell 1, 193-202 (2002). (Pubitemid 41039165)
25. Fjallskog ML, Hessman O, Eriksson B, Janson ET. Upregulated expression of PDGF receptor β in endocrine pancreatic tumors and metastases compared to normal endocrine pancreas. Acta Oncol. 46, 741-746 (2007). (Pubitemid 47123755)
26. Hansel DE, Rahman A, Hermans J et al. Liver metastases arising from welldifferentiated pancreatic endocrine neoplasms demonstrate increased VEGF-C expression. Mod. Pathol. 16, 652-659 (2003). (Pubitemid 36871497)
27. Pietras K, Hanahan D. A multitargeted, metronomic, and maximum-tolerated dose 'chemo-switch' regimen is antiangiogenic, producing objective responses and survival benefit in a mouse model of cancer. J. Clin. Oncol. 23, 939-952 (2005). (Pubitemid 46202314)
28. Kulke MH, Lenz HJ, Meropol NJ et al. Activity of sunitinib in patients with advanced neuroendocrine tumors. J. Clin. Oncol. 26, 3403-3410 (2008).
29. Ebos JM, Kerbel RS. Antiangiogenic therapy: impact on invasion, disease progression, and metastasis. Nat. Rev. Clin. Oncol. 8(6), 316 (2011)